H.C. Wainwright analyst Ram Selvaraju reiterated a Sell rating on Ironwood Pharma (NASDAQ: IRWD) today and set a price target of $12.50. The company’s shares closed on Friday at $18.27.
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.3% and a 42.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Ironwood Pharma is a Moderate Buy with an average price target of $20.88.
See today’s analyst top recommended stocks >>
Based on Ironwood Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $49.38 million. In comparison, last year the company had a GAAP net loss of $44.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient’s lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.
